GeroScience

AX3 ® Bio-Pure Astaxanthin Extends Lifespan in NIH-Funded Longevity Study

Retrieved on: 
Wednesday, December 6, 2023
NIA, Longevity, Research, Dark Ages, Mouse, Male, Life, Interventions, National Institute on Aging, Health, NIH, Ageing, Human, Survival, ITP, Mammal, Bangladesh Technical Education Board, News, Biology, Pharmaceutical industry, GeroScience

HONOLULU, Dec. 6, 2023 /PRNewswire-PRWeb/ -- AX3 Life, a human longevity company, announced breakthrough life extension findings related to its longevity supplement, AX3® Bio-Pure Astaxanthin—a highly bioavailable, pure, and environmentally sustainable form of astaxanthin that safely fights inflammaging and other hallmarks of aging to improve lifespan and healthspan.

Key Points: 
  • The ITP is widely recognized as the gold standard in longevity research and uses lifespan as its primary endpoint.
  • Conducting lifespan studies in humans would require decades, so the ITP's rigorous testing of lifespan in laboratory mice represents the most credible and practical assessment of mammalian lifespan presently available.
  • Results of the multi-year ITP study demonstrated that AX3® Bio-Pure Astaxanthin extended the median lifespan of male mice by 12% with strong statistical significance (p=0.003).
  • "This study underscores why astaxanthin, and in particular AX3® Bio-Pure Astaxanthin, should be a key part of everyone's longevity regimen."

Extracellular Nanoparticles Sourced From Another Species Reverses Biological Age of Rats by More Than 50%

Retrieved on: 
Wednesday, November 1, 2023
Rat, Ageing, Plasma, Stanford University, Human, Coronavirus Scientific Advisory Board, Exosome, Pet, Diabetes, Doctor of Philosophy, Nanoparticle, Research, Stunning, Dark Ages, Rest, Biostatistics, Biology, Animal, UCLA, DNA, Pharmaceutical industry, GeroScience, Genetics, E5

MOUNTAIN VIEW, Calif., Nov. 1, 2023 /PRNewswire/ -- In a groundbreaking research paper titled "Reversal of Biological Age in Multiple Rat Organs by Young Porcine Plasma Fraction" published in GeroScience, scientists have unveiled a remarkable breakthrough in the field of aging biology. A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days. E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.

Key Points: 
  • Peer Reviewed Publication: World's first demonstration of cross species epigenetic transfer that significantly reverses biological age by Scientists at Yuvan Research.
  • A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days.
  • E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.
  • Upon final analysis by Horvath and his team, there was a remarkable 67.4% average reversal in the epigenetic age of treated elderly rats.

Extracellular Nanoparticles Sourced From Another Species Reverses Biological Age of Rats by More Than 50%

Retrieved on: 
Wednesday, November 1, 2023
Rat, Ageing, Plasma, Stanford University, Human, Coronavirus Scientific Advisory Board, Exosome, Pet, Diabetes, Doctor of Philosophy, Nanoparticle, Research, Multimedia, Stunning, Dark Ages, Rest, Biostatistics, Biology, Animal, UCLA, DNA, Pharmaceutical industry, GeroScience, Genetics, E5

MOUNTAIN VIEW, Calif., Oct. 31, 2023 /PRNewswire/ -- In a groundbreaking research paper titled "Reversal of Biological Age in Multiple Rat Organs by Young Porcine Plasma Fraction" published in GeroScience, scientists have unveiled a remarkable breakthrough in the field of aging biology. A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days. E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.

Key Points: 
  • Peer Reviewed Publication: World's first demonstration of cross species epigenetic transfer that significantly reverses biological age by Scientists at Yuvan Research.
  • A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days.
  • E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.
  • Upon final analysis by Horvath and his team, there was a remarkable 67.4% average reversal in the epigenetic age of treated elderly rats.

Aerobic and strength training exercise combined can be an elixir for better brain health in your 80s and 90s, new study finds

Retrieved on: 
Monday, September 25, 2023
People, Cognition, Exercise, University, Education, Life, Test management, Ageing, Quality of life, Hope, Dementia, GeroScience, Thought, DSM-IV codes, Walking, Swimming, Lifting, Jogging, Research, Hand, Montreal Cognitive Assessment, Montreal, Dietary supplement, Toy

Each participant reported their exercise habits and underwent a comprehensive battery of neuropsychological tests that were designed to evaluate various dimensions of cognitive function.

Key Points: 
  • Each participant reported their exercise habits and underwent a comprehensive battery of neuropsychological tests that were designed to evaluate various dimensions of cognitive function.
  • This difference was slight but significant even when controlling for other factors like education and how much people exercised.
  • In addition, the group that did both types of exercises did better in specific cognitive activities, like symbol coding, beyond just the screening results.
  • What’s next
    Some of the next questions we hope to answer include: What types of aerobic and strength exercises are most effective for cognitive health?

Coaching and Education Reduce Alzheimer's Risk Factors and Improve Cognition, According to Early Results from NIA-Funded Study

Retrieved on: 
Thursday, December 22, 2022
Organization, Dementia, University, Patient, Protective factor, Alzheimer's disease, Cognition, Disease, Habit, Neurology, Risk, National Institute on Aging, Cleveland Clinic, Diagnosis, Sleep, Cleveland, Health education, Research, Ageing, Policy, Tutoring, GeroScience

REDWOOD CITY, Calif., Dec. 22, 2022 /PRNewswire/ -- A new study by Neurotrack, the leader in science-backed cognitive health solutions, and the University of Arkansas, finds that after only four months of intervention, health education and cognitive health coaching can lower risks and improve cognition for people at risk of developing Alzheimer's disease and dementia. The results reinforce that changing a few everyday habits can significantly reduce the risk of dementia, and reveal that personalized guidance and encouragement from a coach can be the most effective way to achieve that goal.

Key Points: 
  • The results were statistically significant for both intervention groups, but coaching became more significant when factoring in adherence, simply measured as participating in one session.
  • Health education and health coaching focus on the modifiable risk factors for preventing Alzheimer's disease and dementia, such as nutrition, physical activity, sleep, stress, social engagement, and cognitive activity.
  • These findings come at a critical time as the U.S. population ages, placing more Americans at risk for dementia and Alzheimer's.
  • Health education participants received biweekly education materials focusing on the same modifiable lifestyle factors.

Immunis Initiates Patient Enrollment for Muscle Atrophy Phase 1/2a Clinical Trial

Retrieved on: 
Wednesday, September 21, 2022
Men, Managed Care, General Health, Infectious Diseases, Science, Consumer, Clinical Trials, FDA, Biotechnology, Alternative Medicine, Health, Other Science, Research, Other Health, Women, Seniors, Oncology, Disability, Regenerative medicine, Sarcopenia, Safety, Injection, California Institute for Regenerative Medicine, Hepatitis C, FDA, HBsAg, Osteoarthritis, Inc., Muscle atrophy, Patient, Clinical trial, Male, HIV, Quality of life, Female, STEM, CIRM, Research, Ageing, BMI, University, Immune system, University of California, Irvine Medical Center, Network, Disease, Body mass index, Multisystemic smooth muscle dysfunction syndrome, KOA, Pharmaceutical industry, Dietary supplement, Vaccine, GeroScience

Immunis Inc. , a private biotech company developing a novel treatment for age and disease-related immune decline, initiates patient enrollment for their Phase 1/2a clinical trial to assess Immunis immunomodulatory secretome product, IMM01-STEM, in patients with muscle atrophy.

Key Points: 
  • Immunis Inc. , a private biotech company developing a novel treatment for age and disease-related immune decline, initiates patient enrollment for their Phase 1/2a clinical trial to assess Immunis immunomodulatory secretome product, IMM01-STEM, in patients with muscle atrophy.
  • Every human experiences a decline in immune system health as they age, which contributes to degenerative conditions throughout the body, including muscle atrophy.
  • Age-related muscle atrophy (sarcopenia) and muscle wasting from disuse or disease significantly decreases quality of life.
  • Muscle atrophy is the primary underlying cause of this impaired mobility, with muscle dysfunction expediting cartilage deterioration in patients.